Medytox announced on the 19th that it has received product approval for two types of hyaluronic acid (HA) filler "NURAMIS" from the Serbia Medicines and Medical Devices Agency (ALIMS).
"NURAMIS" is a hyaluronic acid filler independently developed by Medytox, which has proven its efficacy and safety through numerous clinical data over the past decade since its launch. It features minimized residual amounts of cross-linking agent (BDDE) to reduce the possibility of side effects such as swelling and inflammation, while enhancing the efficiency of the cross-linking reaction of hyaluronic acid to strengthen its durability. It is currently sold in a total of 35 countries, including the Middle East, South America, and Asia.
According to Medytox, Serbia, an emerging country in the Eastern European market, is experiencing growth in the skin beauty and anti-aging market due to increased consumer purchasing power resulting from rapid economic growth. In particular, demand for botulinum toxin (botox) products and fillers is on the rise due to the K-beauty craze.
Following this approval, Medytox plans to rapidly penetrate the market by leading with "NURAMIS Deep Lidocaine" and "NURAMIS Volume Lidocaine," which have obtained CE certification from the European Union (EU).
In addition to Serbia, Medytox is accelerating its entry into several other Eastern European countries. Last year, it received additional approval from the Ukrainian Medical Devices Regulatory Authority (UCMCP) for its third factory, which is equipped for mass production, to serve as the manufacturing site for "NURAMIS." It is also continuously strengthening its network with local partners in Georgia, Moldova, and other regions.
A Medytox official noted, "We will quickly promote localized marketing with our partners to ensure that 'NURAMIS' can successfully enter the high-growth potential Serbian market," adding, "We will also focus on new market development to further accelerate the global leap of 'NURAMIS'."